CJC-1295 + IPAMORELIN

CJC-1295 & Ipamorelin

Dual-Action Secretagogue Blend & Growth Hormone Axis Research Compound

Product Overview

CJC-1295 (no DAC) and Ipamorelin is a specialized research blend that integrates two distinct peptide secretagogues designed to act synergistically on the growth hormone (GH) axis. CJC-1295 (Mod GRF 1–29) functions as a GHRH receptor agonist, triggering GH synthesis through cAMP/PKA pathways, whereas Ipamorelin targets the ghrelin receptor (GHS-R1a) to activate calcium signaling. This combination serves as a primary model for investigating GH pulsatility, receptor interactions, and the complex regulation of the hypothalamic–pituitary system.

Key Research Applications

• Synergistic Axis Modulation: Utilized to study how the simultaneous activation of GHRH and ghrelin receptors enhances GH output beyond individual administration.

• GH Pulsatility Studies: Valued for its ability to mimic natural pulsatile release patterns, allowing for the observation of physiological-like GH secretion in experimental models.

• Receptor Cross-Talk Analysis: Frequently targeted in research exploring the interplay between different signaling pathways within the pituitary gland.

• Hypothalamic Regulation: Serves as an analytical tool for investigating the feedback loops and regulatory mechanisms of the central endocrine system.

• Metabolic Signaling Research: Evaluated for its downstream effects on metabolic pathways influenced by growth hormone axis stimulation.

Why Researchers Choose This Blend

• Mechanistic Diversity: Combines two unique pathways—PKA-mediated synthesis and calcium-linked secretion—for a comprehensive study of the GH axis.

• High Analytical Purity: Our CJC-1295 / Ipamorelin Blend is synthesized to a verified purity of 99%, ensuring high-fidelity data and experimental reproducibility.

• Optimized Stability: Provided in a lyophilized (powder) form, which ensures maximum stability and chemical integrity during transport and laboratory storage.

Technical Specifications

• Molecular Formula: CJC-1295: C152_H252_N44_O42 | Ipamorelin: C38_H49_N9_O5

• Molecular Weight: CJC-1295: ~3367.9 Da | Ipamorelin: ~711.9 Da

• Components: 5mg CJC-1295 (no DAC) & 5mg Ipamorelin

• CAS Numbers: 446262-90-4 (CJC) | 170851-70-4 (Ipam)

Research Notice: CJC-1295 (no DAC), Ipamorelin 10mg (Blend) is strictly for laboratory and scientific research use only. It is not approved for human or animal consumption, medical treatment, or therapeutic use.

---

Validated Synthesis & Expedited Fulfillment

Clinical-Grade Synthesis & Purity

Our RUO peptides are engineered via precision synthesis, utilizing meticulously validated protocols to ensure uncompromising accuracy and batch-to-batch consistency. To maintain verified purity, every production lot undergoes independent third-party analysis—including HPLC and mass spectrometry—to confirm molecular identity and a purity of >99%. For expedited research timelines, we provide same-day fulfillment from our U.S. facility for orders placed before 12 PM PST, ensuring rapid and reliable delivery.

References:

1. Bowers CY et al., Endocrinology, 1990 126(2):1165–1171

2. Teichman SL et al., J Clin Endocrinol Metab, 2006 91(2):479–487

3. Kojima M et al., Nature, 1999 402(6762):656–660